1 / 18

Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2 Trial. Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting. Disclosure.

cassie
Download Presentation

Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2 Trial Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

  2. Disclosure Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

  3. Outline Slide Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

  4. Background Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

  5. Primary Objective Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

  6. Secondary Objectives Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

  7. Design Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

  8. Final OPTIMIZE-2 study design Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

  9. Demographics, Baseline Characteristics Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

  10. SRE Rate (Primary Endpoint) Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

  11. Time-to-First SRE Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

  12. Skeletal Morbidity Rate (SMR) Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

  13. Safety Summary Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

  14. Bone Markers Change from Baseline Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

  15. Conclusions Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

  16. Back Ups Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

  17. Number of Infusions Prior to Study Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

  18. Renal Adverse Events Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

More Related